



Attorney's Docket No.: 07334-335001 / MPI99-258CP1

1635

RECEIVED

JUN 04 2003

TECH CENTER 1600/2900

#11/K.T.  
6/6  
Elect.  
B

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : John Bertin et al.  
Serial No. : 09/931,071  
Filed : August 15, 2001  
Title : NOVEL MOLECULES OF THE CARD-RELATED PROTEIN FAMILY AND  
USES THEREOF

Art Unit : 1635  
Examiner : Sean McGarry

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

AMENDMENT AND RESPONSE TO RESTRICTION REQUIREMENT

In response to the Restriction Requirement dated April 24, 2003, applicants elect the invention of Group V, drawn to methods of treating a disorder associated with inappropriate apoptosis by modulating CARD-7 activity or expression. The election is made without traverse.

Prior to examination, please amend the application as indicated on the following sheets, a total of 5 pages.

Enclosed is a check for excess claim fees. Please apply any other charges or credits to Deposit Account No. 06-1050, referencing Attorney Docket No. 07334-335001.

Respectfully submitted,

Date: May 27, 2003

Jack Brennan  
Jack Brennan  
Reg. No. 47,443

Fish & Richardson P.C.  
45 Rockefeller Plaza, Suite 2800  
New York, New York 10111  
Telephone: (212) 765-5070  
Facsimile: (212) 258-2291  
30148803.doc

CERTIFICATE OF MAILING BY FIRST CLASS MAIL

06/02/2003 CNGUYEN 00000113 09931071

01 FC:1202 90.00 OP  
02 FC:1201 252.00 OP

I hereby certify under 37 CFR §1.8(a) that this correspondence is being deposited with the United States Postal Service as first class mail with sufficient postage on the date indicated below and is addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

May 27, 2003  
Date of Deposit  
Carol Tyrrell  
Signature  
Carol Tyrrell  
Typed or Printed Name of Person Signing Certificate

In the Claims:

Please amend the claims as follows:

---

1-16. (Canceled)

17. (Original) A method of treating a disorder associated with inappropriate apoptosis, the method comprising modulating the expression or activity of CARD-7.

18. (New) The method of claim 17, wherein the method comprises administering to an individual a compound that modulates the expression of CARD-7.

19. (New) The method of claim 18, wherein the compound is a small molecule, an antisense nucleic acid molecule, a ribozyme, or a polypeptide.

20. (New) The method of claim 18, wherein the compound increases the expression of CARD-7.

21. (New) The method of claim 18, wherein the compound decreases the expression of CARD-7.

22. (New) The method of claim 21, wherein the compound is an antisense nucleic acid molecule or a ribozyme.

23. (New) The method of claim 18, wherein the disorder is associated with an undesirably high level of apoptotic cell death.

24. (New) The method of claim 18, wherein the disorder is associated with an undesirably low level of apoptotic cell death.

25. (New) The method of claim 18, wherein the disorder is an immune disorder.

26. (New) The method of claim 25, wherein the immune disorder is an inflammatory disorder.

27. (New) The method of claim 18, wherein the disorder is a neurodegenerative disorder.

28. (New) The method of claim 18, wherein the disorder is amyotrophic lateral sclerosis or a cerebral ischemia-induced disorder.

29. (New) The method of claim 17, wherein the method comprises administering to an individual a compound that modulates the activity of CARD-7.

30. (New) The method of claim 29, wherein the compound is a small molecule, an antisense nucleic acid molecule, a ribozyme, or a polypeptide.

31. (New) The method of claim 29, wherein the compound increases the activity of CARD-7.

32. (New) The method of claim 29, wherein the compound decreases the activity of CARD-7.

33. (New) The method of claim 32, wherein the compound is a small molecule, an antisense nucleic acid molecule, a ribozyme, or a polypeptide.

34. (New) The method of claim 29, wherein the disorder is associated with an undesirably high level of apoptotic cell death.

35. (New) The method of claim 29, wherein the disorder is associated with an undesirably low level of apoptotic cell death.

Applicant : John Bertin et al.  
Serial No. : 09/931,071  
Filed : August 15, 2001  
Page : 4 of 5

Attorney's Docket No.: 07334-335001 / MPI99-258CP1

36. (New) The method of claim 29, wherein the disorder is an immune disorder.

37. (New) The method of claim 36, wherein the immune disorder is an inflammatory disorder.

38. (New) The method of claim 29, wherein the disorder is a neurodegenerative disorder.

39. (New) The method of claim 29, wherein the disorder is amyotrophic lateral sclerosis or a cerebral ischemia-induced disorder.

---

Applicant : John Bertin et al.  
Serial No. : 09/931,071  
Filed : August 15, 2001  
Page : 5 of 5

Attorney's Docket No.: 07334-335001 / MPI99-258CP1

REMARKS

Claims 17-39 are pending in the application. Claims 1-16 have been canceled and claims 18-39 have been added. The application has been amended to cancel those claims drawn to non-elected inventions and to add new claims directed to the invention of Group V. Support for the new claims can be found in the specification at, e.g., page 5, line 29, to page 7, line 19, and page 12, line 25, to page 13, line 18. These amendments add no new matter.